| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | uPAR |
| Uniprot No | Q03405 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-303aa |
| 氨基酸序列 | LRCMQCKTNGDCRVEECALGQDLCRTTIVRLWEEGEELELVEKSCTHSEK TNRTLSYRTGLKITSLTEVVCGLDLCNQGNSGRAVTYSRSRYLECISCGS SDMSCERGRHQSLQCRSPEEQCLDVVTHWIQEGEEGRPKDDRHLRGCGYL PGCPGSNGFHNNDTFHFLKCCNTTKCNEGPILELENLPQNGRQCYSCKGN STHGCSSEETFLIDCRGPMNQCLVATGTHEPKNQSYMVRGCATASMCQHA HLGDAFSMNHIDVSCCTKSGCNHPDLDVQYR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于uPAR重组蛋白的3篇参考文献示例：
---
1. **文献名称**: "The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator"
**作者**: Behrendt, N., et al.
**摘要**: 该研究通过重组表达uPAR的配体结合结构域，解析了其与尿激酶(uPA)的特异性结合机制，并证实该结构域在细胞迁移和信号传导中的关键作用。
---
2. **文献名称**: "Crystal structure of the human urokinase plasminogen activator receptor (uPAR) in complex with uPA"
**作者**: Ploug, M., et al.
**摘要**: 利用重组uPAR蛋白与uPA的共结晶技术，首次揭示了uPAR的三维结构，阐明了其与配体相互作用的分子基础及潜在的药物靶点。
---
3. **文献名称**: "Soluble urokinase receptor (suPAR) in pathological conditions"
**作者**: Rønne, E., et al.
**摘要**: 通过重组表达可溶性uPAR(suPAR)，研究其在炎症、癌症和肾病中的生物学功能，发现suPAR可作为疾病标志物并参与病理微环境调控。
---
这些文献涵盖了uPAR重组蛋白的结构解析、配体互作机制及病理功能研究领域。如需具体文章链接或补充更多文献，可进一步说明。
**Background of uPAR Recombinant Protein**
The urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein that plays a pivotal role in extracellular matrix remodeling, cell adhesion, migration, and signaling. It binds with high affinity to its ligand, urokinase plasminogen activator (uPA), forming a proteolytic system critical for activating plasminogen to plasmin, a broad-spectrum protease involved in fibrinolysis and tissue remodeling. uPAR is composed of three homologous domains (D1. D2. D3) and interacts with integrins and other receptors to regulate cell signaling pathways, including those influencing inflammation, angiogenesis, and cancer metastasis.
Dysregulation of uPAR is implicated in pathological conditions such as cancer progression, chronic inflammation, and fibrosis. Overexpression of uPAR correlates with poor prognosis in malignancies by enhancing tumor cell invasion and metastasis. These attributes make uPAR a promising therapeutic target and diagnostic biomarker.
Recombinant uPAR (ruPAR) proteins are engineered to mimic native uPAR's structure and function, typically produced using mammalian expression systems (e.g., CHO cells) or *E. coli* for cost-effective production. Soluble forms of uPAR (suPAR), lacking the GPI anchor, are commonly generated to study ligand interactions, receptor dimerization, and downstream signaling *in vitro*. ruPAR is instrumental in drug discovery, enabling high-throughput screening of inhibitors targeting uPAR-uPA interactions. It also serves as a tool to investigate uPAR's role in cellular processes and validate its involvement in disease mechanisms.
Despite challenges in preserving post-translational modifications (e.g., glycosylation) in prokaryotic systems, advances in protein engineering have improved ruPAR functionality. Its applications span basic research, therapeutic development, and diagnostic assays, underscoring its versatility in biomedical studies.
×
